Mucormycosis and Its Upsurge During COVID-19 Epidemic: An Updated Review

Knowledge on mucormycosis among nursing Indian students in the state of Gujarat

“…Mucormycosis is one of the prominent consequences that have been linked to this illness. It is an opportunistic infection brought on by members of the Order Mucorales, which are found all over the world and have long been documented as a laboratory contaminant [ 4 ].…”

“…Numerous risk factors, such as type 2 diabetes, ketoacidosis, haematological malignancies, organ transplant recipients, and chemotherapy patients, can lead to the development of mucormycosis. Rhizopus is discovered to be the most prevalent etiological agent among the several etiological agents, and rhino-cerebral is the most prevalent clinical presentation [ 4 ]. Normal immune function was hampered by COVID-19 infection and subsequent treatment with steroids and immune modulatory drugs.…”

Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature

“…The most prevalent genus causing clinical mucormycosis is Rhizopus (two main species) [ 25 ], followed by the genus Mucor (twelve species up to date) [ 24 ], Lichtheimia , and Rhizomucor ; other less frequent pathogenic species are occasionally reported [ 26 , 27 ]. The fast growth, airborne spores, and the thermotolerance of these ubiquitarian saprotroph moulds enable them to grow at human body temperature: these features explain their pathogenic activity in patients with specific risk factors, including SARS-CoV-2 infection and treatments [ 28 , 29 ], as listed in Table 1 [ 20 , 26 , 30 ].…”

“…The most prevalent genus causing clinical mucormycosis is Rhizopus (two main species) [25], followed by the genus Mucor (twelve species up to date) [24], Lichtheimia, and Rhizomucor; other less frequent pathogenic species are occasionally reported [26,27]. The fast growth, airborne spores, and the thermotolerance of these ubiquitarian saprotroph moulds enable them to grow at human body temperature: these features explain their pathogenic activity in patients with specific risk factors, including SARS-CoV-2 infection and treatments [28,29], as listed in Table 1 [20,26,30]. Iatrogenic/secondary: hematopoietic stem cell (HSCT); solid organ transplant Preventive or therapeutic antimycotic drugs (voriconazole, itraconazole, or caspofungin) [35] BTK inhibitor [12,[15][16][17][18][19] SARS-CoV-2 infecion and treatment [28,29] Little is known so far about these fungal cell structures, especially regarding the components of their cell wall [36] as well as their biology and metabolism, and this has a major clinically negative impact, both on the diagnostic side (laboratory tests on serum or other human fluids) and on the therapeutic side (the correct administration of specific drugs).…”